Aberrant expression of miR-۴۵۱۶ in breast cancer tissue and its correlation with clinicopathological factors

Publish Year: 1399
نوع سند: مقاله کنفرانسی
زبان: English
View: 271

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

CIGS16_237

تاریخ نمایه سازی: 14 اردیبهشت 1400

Abstract:

Background and Aim: miRNAs are small noncoding RNA with ۲۰-۲۵nt in length that known to be aberrantly expressed in various diseases, including cancer. MiR-۴۵۱۶ dysregulation was observed in various cancers; its overexpression has been reported in papillary thyroid and prostate cancer. In addition, reduced miR-۴۵۱۶ expression inhibits tumor growth and induces apoptosis in glioblastoma. Unlike the other cancers, still there is no information available on mir-۴۵۱۶ in breast cancer. Therefore, in this study we evaluated miR-۴۵۱۶ expression and association with clinopathological factors in breast cancer.Methods: in this study ۳۵ paraffin-embedded breast cancer tumor tissues with adjacent healthy tissue were enrolled. The total RNA was extracted with MN kit (NucleoSpin® totalRNA FFPE- Germany). The miRNA cDNA was synthesized in polyadenylation method. Real-Time PCR was used to investigate miR-۴۵۱۶ expression. U۶ was selected as internal reference gene for normalization of real-time RT-PCR. Relative gene expression was analyzed by the ۲−ΔΔCt method. Eventually we analyzed data using statistical methods including t-test and one-way ANOVA.Results: According to the analysis, miR-۴۵۱۶ expression was significantly downregulated in tumor tissues compared to adjacent nontumor tissues (P = ۰.۰۰۱). In addition significant decrease in expression of miR-۴۵۱۶ was observed in grade ۲ tumors (P = ۰.۰۰۳).Conclusion: Taken together, these findings indicate that miR-۴۵۱۶ may act as tumor suppressor in breast cancer. In addition, miR-۴۵۱۶ expression is associated with high grade of breast cancer.

Authors

Roya Aliasgari

MSc of genetics, Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran,

somayeh Reiisi

Assistance professor, Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Irans,